[HTML][HTML] ER-positive and BRCA2-mutated breast cancer: a literature review
PC Li, YF Zhu, WM Cao, B Li - European Journal of Medical Research, 2024 - Springer
PC Li, YF Zhu, WM Cao, B Li
European Journal of Medical Research, 2024•SpringerBRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of
onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate
cancer). Almost 70–80% of BRCA2-mutated BC are estrogen receptor (ER)-positive, which
is a particular type of ER-positive BC that differs from sporadic ER-positive BC. This article
reviews the clinicopathological features, treatment, and prognosis of ER-positive and
BRCA2-mutated BC to provide a reference for clinical decision-making.
onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate
cancer). Almost 70–80% of BRCA2-mutated BC are estrogen receptor (ER)-positive, which
is a particular type of ER-positive BC that differs from sporadic ER-positive BC. This article
reviews the clinicopathological features, treatment, and prognosis of ER-positive and
BRCA2-mutated BC to provide a reference for clinical decision-making.
Abstract
BRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate cancer). Almost 70–80% of BRCA2-mutated BC are estrogen receptor (ER)-positive, which is a particular type of ER-positive BC that differs from sporadic ER-positive BC. This article reviews the clinicopathological features, treatment, and prognosis of ER-positive and BRCA2-mutated BC to provide a reference for clinical decision-making.
Springer
